Clinical Trial

Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2026 (before its estimated August 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-19
notable Primary completion pushed: 2026-05-13 -> 2026-08-13 2026-07-19
minor Completion pushed: 2026-06-10 -> 2026-10-10 2026-07-19
Trial Details
NCT Number NCT07370155
Lead Sponsor Ashvattha Therapeutics, Inc.
Conditions Healthy Volunteers
Enrollment 36 participants
Start Date 2026-01-29
Primary Completion 2026-08-13 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-17